Clinicopathological analysis of claudin 18.2 focusing on intratumoral heterogeneity and survival in patients with metastatic or unresectable gastric cancer
Characterizing unresectable, metastatic, or recurrent GC with positive CLDN18.2 expression and evaluating intratumoral heterogeneity and prognostic implications of various therapeutics help advance treatment strategies and develop new therapies for patients with GC.
Authors
- T.-Y. Kim
- Yoonjin Kwak (ORCID: https://orcid.org/0000-0001-5314-2465)
- Dali Han (ORCID: https://orcid.org/0000-0001-8983-018X)
- Do‐Youn Oh (ORCID: https://orcid.org/0000-0003-1663-9901)
- Seock‐Ah Im (ORCID: https://orcid.org/0000-0002-5396-6533)
- Hye Seung Lee (ORCID: https://orcid.org/0000-0002-1667-7986)
- Soo Kyung Nam (ORCID: https://orcid.org/0000-0002-4372-1516)
Institutions
- Seoul National University (KR)
- Cancer Research Institute (US)
- New Generation University College (ET)
- Seoul National University Hospital (KR)
- Astellas Pharma (South Korea) (KR)
Publication Details
- Journal
- ESMO Open
- Published
- 2024-11-29
- DOI
- https://doi.org/10.1016/j.esmoop.2024.104000
- Citations
- 26
- Primary Topic
- Neurological Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.43
Funders
- Astellas Pharma
- Astellas Foundation for Research on Metabolic Disorders